ARO-AAT Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ARO-AAT Growth

1. Strong Histologic and Fibrosis Improvement Data

One of the biggest growth drivers for fazirsiran is its ability to demonstrate not only biomarker reductions but also improvement in underlying liver pathology.

In the Phase II AROAAT-2002 study:

• Median liver Z-AAT accumulation decreased by 83%
• Histologic globule burden declined by 69%
• Fibrosis regression occurred in 58% (7 of 12) patients receiving 200 mg therapy.

The placebo-controlled SEQUOIA Phase II study further showed:

• Serum Z-AAT reductions up to 94%
• Median liver Z-AAT reduction of 93%
• Histologic improvement in liver inflammation and fibrosis versus placebo.

These findings are highly important because liver fibrosis reversal is considered a major therapeutic objective in AATD-associated liver disease.

2. Potential First-in-Class Therapy for AATD Liver Disease

There are currently no approved pharmacologic therapies specifically targeting liver disease caused by AATD; liver transplantation remains the only curative option in advanced disease.

Fazirsiran directly targets production of mutant Z-AAT protein, the underlying driver of hepatocyte injury and fibrosis. This disease-modifying mechanism significantly differentiates the therapy from supportive care approaches and positions it as a potentially first-in-class treatment.

3. Regulatory Advantages and Orphan Disease Positioning

Fazirsiran has received:

• Breakthrough Therapy Designation from the FDA
• Orphan Drug Designation for AATD liver disease.

These designations may provide:

• Accelerated regulatory interactions
• Potentially faster review timelines
• Market exclusivity benefits
• Premium orphan-drug pricing opportunities

Rare liver diseases often support high-value commercial models because of significant unmet need and limited competition.

4. Durable RNAi Silencing Enables Infrequent Dosing

Fazirsiran uses Arrowhead's TRiM(TM) RNAi platform to silence mutant SERPINA1 gene expression in hepatocytes.

Clinical studies demonstrated sustained suppression of Z-AAT with:

• Subcutaneous administration
• Dosing every 12 weeks in maintenance phases.

Infrequent dosing could provide important advantages in:

• Patient adherence
• Treatment convenience
• Long-term persistence
• Reduced healthcare burden

compared with chronic infusion-based therapies used in other rare diseases.

5. Strategic Takeda Partnership Strengthens Commercialization Potential

Takeda entered a major collaboration with Arrowhead in 2020 to co-develop and commercialize fazirsiran.

Under the agreement:

• Arrowhead received $300 million upfront
• Potential milestone payments may total up to $740 million
• The companies will co-commercialize in the U.S. under a 50/50 profit split.

Takeda's strong gastroenterology and rare disease infrastructure substantially enhances:

• Global development capability
• Regulatory execution
• Commercial launch preparedness

particularly in hepatology-focused markets.

ARO-AAT Recent Developments

Takeda Pharmaceutical Company announced a collaboration and licensing agreement to develop ARO-AAT, a Phase II investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression.

"ARO-AAT Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ARO-AAT for potential indication like Alpha 1-antitrypsin deficiency in the 7MM. A detailed picture of ARO-AAT's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ARO-AAT for potential indications. The ARO-AAT market report provides insights about ARO-AAT's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ARO-AAT performance, future market assessments inclusive of the ARO-AAT market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ARO-AAT sales forecasts, along with factors driving its market.

ARO-AAT Drug Summary

ARO-AAT is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). The therapy uses Arrowhead's proprietary TRiM platform to selectively silence the messenger RNA responsible for producing the mutant Z-alpha-1 antitrypsin (Z-AAT) protein in hepatocytes, thereby reducing the toxic accumulation of misfolded protein that drives liver inflammation, fibrosis, and progressive hepatic damage. Administered as a subcutaneous injection, ARO-AAT is designed to provide durable suppression of mutant protein expression with infrequent dosing intervals. Clinical studies, including the SEQUOIA and AROAAT2002 trials, have demonstrated substantial reductions in serum and intrahepatic Z-AAT levels, along with improvements in liver histology and fibrosis markers, supporting its potential as a disease-modifying therapy for AATD-related liver disease. The drug has received Breakthrough Therapy Designation from the US Food and Drug Administration, and ongoing studies continue to evaluate its long-term safety, tolerability, and ability to prevent progression to cirrhosis and liver failure. The report provides ARO-AAT's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ARO-AAT Market Report

The report provides insights into:

• A comprehensive product overview including the ARO-AAT MoA, description, dosage and administration, research and development activities in potential indication like Alpha 1-antitrypsin deficiency.
• Elaborated details on ARO-AAT regulatory milestones and other development activities have been provided in ARO-AAT market report.
• The report also highlights ARO-AAT's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ARO-AAT market report also covers the patents information, generic entry and impact on cost cut.
• The ARO-AAT market report contains current and forecasted ARO-AAT sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ARO-AAT market report also features the SWOT analysis with analyst views for ARO-AAT in potential indications.

Methodology:

The ARO-AAT market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARO-AAT Analytical Perspective by DelveInsight

• In-depth ARO-AAT Market Assessment

This ARO-AAT sales market forecast report provides a detailed market assessment of ARO-AAT for potential indication like Alpha 1-antitrypsin deficiency in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ARO-AAT sales data uptil 2034.

• ARO-AAT Clinical Assessment

The ARO-AAT market report provides the clinical trials information of ARO-AAT for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ARO-AAT Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ARO-AAT Market Potential & Revenue Forecast

• Projected market size for the ARO-AAT and its key indications
• Estimated ARO-AAT sales potential (ARO-AAT peak sales forecasts)
• ARO-AAT Pricing strategies and reimbursement landscape

ARO-AAT Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ARO-AAT Market positioning compared to existing treatments
• ARO-AAT Strengths & weaknesses relative to competitors

ARO-AAT Regulatory & Commercial Milestones

• ARO-AAT Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ARO-AAT Clinical Differentiation

• ARO-AAT Efficacy & safety advantages over existing drugs
• ARO-AAT Unique selling points

ARO-AAT Market Report Highlights

• In the coming years, the ARO-AAT market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ARO-AAT companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARO-AAT's dominance.
• Other emerging products for Alpha 1-antitrypsin deficiency are expected to give tough market competition to ARO-AAT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARO-AAT in potential indications.
• Analyse ARO-AAT cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ARO-AAT sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ARO-AAT in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ARO-AAT? How strong is ARO-AAT's clinical and commercial performance?
• What is ARO-AAT's clinical trial status in each individual indications such as Alpha 1-antitrypsin deficiency and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARO-AAT Manufacturers?
• What are the key designations that have been granted to ARO-AAT for potential indications? How are they going to impact ARO-AAT's penetration in various geographies?
• What is the current and forecasted ARO-AAT market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ARO-AAT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARO-AAT for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ARO-AAT? What is the duration of therapy and what are the geographical variations in cost per patient?